+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence

Nov 27, 2019, 11:02 IST
PTI
New Delhi, Nov 27 () Biotechnology major Biocon on Wednesday said that US health regulator has approved its and Mylan's supplemental biologics licence application for a drug substance to be manufactured at its new facility in Bengaluru.

"Biocon and Mylan's supplemental biologics licence application (sBLA)..for pegfilgrastim drug substance to be manufactured in Biocon's new Biologics manufacturing facility has been approved by the US Food and Drug Administration (USFDA)," the company said in a filing to BSE.

Advertisement

This additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its arm Biocon Biologics and Mylan to scale up capacity multi-fold and address the growing market opportunities in US and other global markets, the company said.

Biocon Biologics CEO Christiane Hamacher said, "This approval will help us better meet global patient needs for Fulphila, a high quality biosimilar pegfilgrastim co developed with Mylan and manufactured by Biocon Biologics".

Biocon Biologics, through its partner Mylan, has commercialised three of its co-developed biosimilars in developed markets like the US, Canada, the European Union and Australia.

The USFDA had conducted pre-approval inspection of this new drug substance manufacturing facility from September 10-19, 2019.

Advertisement

Shares of the company were trading at Rs 277.45 apiece in morning trade on BSE. SID ANS ANS

(This story has not been edited by www.businessinsider.in and is auto–generated from a syndicated feed we subscribe to.)
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article